Clinical Trial Update: Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CP-751,871 in combination with docetaxel and prednisone in hormone-insensitive prostate cancer has completed and posted results in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CP-751,871 (dalotuzumab)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-04-11